Table 1.

Participant characteristics

	ALL (n=71)	Female (n=48)	Male (n=23)	P value
Age	71 ± 5	71 ± 6	71 ± 5	p=.987
Race, white (%)	68 (96%)	45 (94%)	23 (100%)
Non-white (%)	3 (4%)	3 (6%)	0 (0%)
HTN (≥140/90)	16	9	7
HTN medication	(Y) 24	(Y) 12	(Y) 11
Cholesterol (Total, HDL)	184±24, 32±15	200±38, 67±18	167±32, 48±12
ASCVD Risk Score	17.2±4.9	13.7±9.8	20.6±8.3	p=.007
Workload (W/kg)	0.80±0.27	0.74±0.29	0.93±0.18	p=.004
APOE4 carrier	(+) = 21/71	(+) = 14/48	(+) = 7/23	p=.813
Aβ Deposition	1.09 ± 0.17 [0.86 to 1.6]	1.09 ± 0.18 [0.86 to 1.6]	1.1 ± 0.18 [0.92 to 1.6]	p=.701
CVR	5.55 ± 5.29	5.38 ± 5.54	5.87 ± 4.83	p=.719
Stroop ratio	0.52 ± 0.12	0.51 ± 0.12	0.54 ± 0.13	p=.458

Aβ = amyloid-β; CVR = cerebrovascular response to moderate-intensity aerobic exercise; Aβ = amyloid-β; [Range]; W= Watts at moderate intensity exercise workload; kg BW = kilograms of body weight; ASCVD Risk Score= Atherosclerotic Cardiovascular Disease Risk Score; (+)=APOE4 carrier; (Y)=Yes; HTN=hypertension. Values are depicted as mean ± SD.

Among 71 total participants, there were no differences between female and male participants in cognitive performance, age, Aβ, proportion of APOE4(+) or CVR (Table 1). As expected, male participants performed exercise at a greater normalized workload compared to females and had a higher ASCVD score.